---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001020"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:39:25.370885+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCryst Q4 ORLADEYO rev $124.2M (+36.6%); FY2025 guidance raised; faces generic challenge

## Summary
- Q4 ORLADEYO net revenue $124.2M (+36.6% YoY); full year 2024 net revenue $437.7M (+34.3% YoY).
- FY 2024 GAAP operating loss $2.5M; non-GAAP operating profit $62.9M (excl. stock-based comp).
- FY 2025 ORLADEYO revenue guidance raised to $535-550M from $515-535M; expects positive EPS in 2H 2025.
- Annora Pharma filed ANDA for generic ORLADEYO; company intends to vigorously defend three patents expiring 2039.
- NDA submission in 2025 for pediatric ORLADEYO granule (ages 2-11); initial data from BCX17725 and avoralstat expected by year-end.

## SEC filing metadata
- accession: 0001171843-25-001020
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/0001171843-25-001020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/f8k_022425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001020
- JSON: https://secwatch.observer/filing/0001171843-25-001020.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.